Front-line Multiple Myeloma Treatment Patterns from a US Community Network, 2015-2022

R. Steve Paulson's study analyzes real-world treatment patterns for newly diagnosed multiple myeloma (NDMM) using data from Texas Oncology. The dataset includes 3592 patients who initiated front-line treatment between January 2015 and December 2022. It describes temporal trends in the adoption of triplet and quadruplet regimens, including daratumumab-based therapies.

Use Cases

• Analyzing temporal trends in front-line multiple myeloma treatment adoption based on the 2015-2022 time range mentioned in the description
• Studying the real-world uptake of specific drug regimens like daratumumab-based therapies referenced in the results
• Comparing treatment patterns between community-based oncology networks and clinical trial settings based on the study's stated focus
• Modeling factors influencing the adoption of quadruplet regimens based on the low uptake rate highlighted in the conclusion

Strengths

• Includes 3592 patient records, providing a substantial sample for analysis
• Covers an 8-year time range (2015-2022), enabling longitudinal trend analysis
• Focuses on real-world data from a community oncology network, addressing a noted evidence gap
• Released under a permissive CC-BY-4.0 license, facilitating reuse

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count for the underlying data is unknown, which may limit suitability assessment
• Data is limited to a single US community oncology network (Texas Oncology), which may not be nationally representative

Provenance

Source

Texas Oncology community network, as stated in the methods.

Collection Method

Retrospective, observational study analyzing structured and unstructured medical records.

Time Range

January 2015 to December 2022

Freshness

Last updated 2026-04 22 11:35:15; freshness should be verified

Geography

United States, specifically Texas Oncology centers